Alzheimer’s Disease – Unmet Need – Unmet Need – Early Alzheimer’s Disease (US/EU)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla) are modestly effective in reducing cognitive and functional decline, require frequent IV infusions, and carry ARIA-related safety risks. Emerging DMTs with near-term launch potential (e.g., subcutaneous lecanemab, Eli Lilly’s remternetug, Roche’s trontinemab, Novo Nordisk’s semaglutide) may deliver greater biomarker and/or clinical efficacy, lower ARIA risk, or improved delivery profiles. This report examines the influence of a key clinical (e.g., reduction of cognitive and functional decline, plaque clearance, ARIA risk) and nonclinical (i.e., out-of-pocket cost) attributes on neurologists’ prescribing decisions and assesses the key opportunities for differentiation from Leqembi, Kisunla, and procognitive symptomatics in the early AD market.
QUESTIONS ANSWERED
- How important is a therapy’s effect on cognition, function, or biomarker outcomes in neurologists’ selection of a therapy for early AD?
- How do neurologists rate Leqembi, Kisunla, and procognitive symptomatics on their overall performance in the treatment of early AD and on key individual attributes?
- Based on conjoint analysis and TPP simulation, what trade-offs among efficacy, safety, treatment duration, and other factors are neurologists willing to make when considering a hypothetical DMT for early AD?
PRODUCT DESCRIPTION
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 32 European neurologists fielded in December 2023
Key companies: AbbVie, Biogen, Eisai, Eli Lilly, Roche
Key drugs: Leqembi, Kisunla, donepezil, galantamine, Namzaric, rivastigmine patch
